PTEN, PIK3CA, p-AKT, and p-p70S6K Status

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084 · see citing works

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · see citing works

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

ErbB receptors and signaling pathways in cancer

Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · see citing works

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nahta, R., Yu, D., Hung, M., Hortobágyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916 · see citing works

PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877 · see citing works

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829 · see citing works

Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals

Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 813 · see citing works

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766 · see citing works

The PIK3CA gene is mutated with high frequency in human breast cancers

Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology &amp; Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665 · see citing works

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 611 · see citing works

Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

Esteva, F. J., Valero, V., Booser, D. J., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566 · see citing works

Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2 : Analysis of 10,000 Individuals

Frank, T. S., Deffenbaugh, A. M., Reid, J., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 557 · see citing works

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524 · see citing works

Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells

Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 505 · see citing works

Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast

Perren, A. A., Weng, L., Boag, A. H., Ziebold, U., Thakore, K. S., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 379 · see citing works

Measures of Response: RECIST, WHO, and New Alternatives

Jaffe, C. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5599 · Cited by 302 · see citing works

Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer

Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 296 · see citing works

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

Pérez‐Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292 · see citing works

The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling

Vázquez, F., & Sellers, W. R. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00032-3 · Cited by 224 · see citing works

ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells

Klos, K. S., Wyszomierski, S. L., Sun, M., Tan, M., Zhou, X., Li, P., Yang, W., Yin, G., Hittelman, W. N., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4559 · Cited by 201 · see citing works

Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency

Lu, C., Wyszomierski, S. L., Tseng, L., Sun, M.-H., Lan, K., Neal, C. L., Mills, G. B., Hortobágyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 201 · see citing works

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 168 · see citing works

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

Fujita, T., Doihara, H., Kawasaki, K., Takabatake, D., Takahashi, H., Washio, K., Tsukuda, K., Ogasawara, Y., & Shimizu, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602926 · Cited by 156 · see citing works

Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers

Xia, W., Husain, I., Liu, L.-H., Bacus, S. S., Saini, S., Spohn, J., Pry, K. J., Westlund, R. E., Stein, S. H., & Spector, N. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2101 · Cited by 146 · see citing works

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

Kurokawa, H., & Arteaga, C. L. (2003) · PubMed · Cited by 139 · see citing works

Immunohistochemical Detection of c-erbB-2 and p53 in Benign Breast Disease and Breast Cancer Risk

Rohan, T. E., Hartwick, W. J., Miller, A. B., & Kandel, R. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.17.1262 · Cited by 106 · see citing works

Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.

Emens, L. A. (2005) · PubMed · Cited by 102 · see citing works

Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

Chan, C. T., Metz, M. Z., & Kane, S. E. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7715-1 · Cited by 90 · see citing works

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

Mariani, G., Fasolo, A., Benedictis, E. D., & Gianni, L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1298 · Cited by 80 · see citing works

Oestrogen receptor status of breast carcinoma: Allred/H score conversion table

Shousha, S. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03075.x · Cited by 77 · see citing works

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M. G., Fenocchio, D., Stocchi, L., Foglietta, J., Ludovini, V., Minenza, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn681 · Cited by 72 · see citing works

Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies

Singer, C. F., Köstler, W. J., & Hudelist, G. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.003 · Cited by 51 · see citing works

HER-2-positive metastatic breast cancer: trastuzumab and beyond

Metro, G., Mottolese, M., & Fabi, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2583 · Cited by 49 · see citing works

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer

Mills, G. B. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.011 · Cited by 46 · see citing works

Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma

Tokunaga, E., Oki, E., Kimura, Y., Yamanaka, T., Egashira, A., Nishida, K., Koga, T., Morita, M., Kakeji, Y., & Maehara, Y. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9295-8 · Cited by 41 · see citing works

PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough

Hynes, N. E., & Dey, J. H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.004 · Cited by 38 · see citing works

Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer

Zhou, Y., Pan, Y., Zhang, S., Shi, X., Ning, T., & Ke, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603838 · Cited by 35 · see citing works

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy

Yonemori, K., Tsuta, K., Shimizu, C., Hatanaka, Y., Hashizume, K., Ono, M., Kouno, T., Ando, M., Tamura, K., Katsumata, N., et al. (2008) · Medical Oncology · doi:10.1007/s12032-008-9127-2 · Cited by 31 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

PTEN loss in the continuum of common cancers, rare syndromes and mouse models

Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3037 · Cited by 793 · see citing works

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494 · see citing works

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

André, F., O'Regan, R. M., Özgüroğlu, M., Toi, M., Xu, B., Jérusalem, G., Masuda, N., Wilks, S. T., Arena, F. P., Isaacs, C. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493 · see citing works

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 465 · see citing works

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 372 · see citing works

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Hurvitz, S. A., André, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306 · see citing works

Towards personalized treatment for early stage HER2-positive breast cancer

Goutsouliak, K., Veeraraghavan, J., Sethunath, V., Angelis, C. D., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 285 · see citing works

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance

Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 276 · see citing works

Therapeutic Targeting of Cancers with Loss of PTEN Function

Dillon, L. M., & Miller, T. W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 240 · see citing works

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

Yang, S. X., Polley, E. C., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 239 · see citing works

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Gallardo, A., Lerma, E., Escuín, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 230 · see citing works

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Chandarlapaty, S., Sakr, R. A., Giri, D. D., Patil, S. N., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N. X., Hudis, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 229 · see citing works

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Baselga, J. M., Phillips, G. D. L., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., & Pegram, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2499 · Cited by 229 · see citing works

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy

Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209 · see citing works

Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203 · see citing works

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

Chaft, J. E., Arcila, M. E., Paik, P. K., Lau, C., Riely, G. J., Pietanza, M. C., Zakowski, M. F., Rusch, V. W., Sima, C. S., Ladanyi, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0692 · Cited by 202 · see citing works

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 192 · see citing works

PI3K mutations in breast cancer: prognostic and therapeutic implications

Mukohara, T. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s60696 · Cited by 191 · see citing works

PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

Čížková, M., Susini, A., Vacher, S., Cizeron-Clairac, G., Andrieu, C., Driouch, K., Fourme, E., Lidereau, R., & Bièche, I. (2012) · Breast Cancer Research · doi:10.1186/bcr3113 · Cited by 188 · see citing works

Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer

Hernandez-Aya, L. F., & Gonzalez-Angulo, A. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0402 · Cited by 178 · see citing works

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

André, F., Hurvitz, S. A., Fasolo, A., Tseng, L., Jérusalem, G., Wilks, S. T., O'Regan, R. M., Isaacs, C. J., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 166 · see citing works

Salvianolic acid A attenuates CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways

Wang, R., Song, F., Li, S., Wu, B., Gu, Y., & Yuan, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s194787 · Cited by 160 · see citing works

Gastric cancer: somatic genetics as a guide to therapy

Zhang, X., & Zhang, P.-Y. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104171 · Cited by 159 · see citing works

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data

Zardavas, D., Phillips, W. A., & Loi, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3605 · Cited by 153 · see citing works

Current approaches and future directions in the treatment of HER2-positive breast cancer

Hurvitz, S. A., Hu, Y., O’Brien, N. A., & Finn, R. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 151 · see citing works

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Ferrari, A., Vincent-Salomon, A., Pivot, X., Sertier, A.-S., Thomas, E., Tonon, L., Boyault, S., Mulugeta, E., Treilleux, I., MacGrogan, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms12222 · Cited by 150 · see citing works

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 151 · see citing works

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

Miller, T. W., & Hosford, S. R. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 145 · see citing works

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab

Jensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 136 · see citing works

Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes

Mohan, N., Shen, Y., Endo, Y., ElZarrad, M. K., & Wu, W. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0741 · Cited by 132 · see citing works

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 130 · see citing works

Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue

Potts, S. J., Krueger, J. S., Landis, N. D., Eberhard, D. A., Young, G. D., Schmechel, S. C., & Lange, H. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.91 · Cited by 125 · see citing works

Signaling cross-talk in the resistance to HER family receptor targeted therapy

Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 115 · see citing works

PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling

Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L. Y., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2014) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 110 · see citing works

Targeted therapies: how personal should we go?

Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 111 · see citing works

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Guarneri, V., Dieci, M. V., Frassoldati, A., Maiorana, A., Ficarra, G., Bettelli, S. R., Tagliafico, E., Bicciato, S., Generali, D., Cagossi, K., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0138 · Cited by 109 · see citing works

Tumour suppressor genes in chemotherapeutic drug response

Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 109 · see citing works

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2642 · Cited by 106 · see citing works

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

Singh, J. C., Jhaveri, K. L., & Esteva, F. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.388 · Cited by 105 · see citing works

Changing Treatment Paradigms in Metastatic Breast Cancer

Santa-Maria, C. A., & Gradishar, W. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1198 · Cited by 104 · see citing works

The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab

Eto, K., Iwatsuki, M., Watanabe, M., Ida, S., Ishimoto, T., Iwagami, S., Baba, Y., Sakamoto, Y., Miyamoto, Y., Yoshida, N., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3325-7 · Cited by 103 · see citing works

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

Kim, S., Wildiers, H. P. M. W., Krop, I. E., Smitt, M. C., Yu, R., de Haas, S. L., & González-Martı́n, A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30276 · Cited by 101 · see citing works

Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer

Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 99 · see citing works

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Rimawi, M. F., Angelis, C. D., Contreras, A., Pareja, F. G., Geyer, F. C., Burke, K. A., Herrera, S., Wang, T., Mayer, I. A., Forero, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4533-9 · Cited by 98 · see citing works

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma

Peiró, G., Ortiz-Martínez, F., Gallardo, A., Perez‐Balaguer, A., Sánchez–Payá, J., Ponce, J., Tibau, A., López-Vilaró, L., Escuín, D., Adrover, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.327 · Cited by 95 · see citing works

Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.

Kechagioglou, P., Papi, R. M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, P., Nonni, A., Zografos, G., Kyriakidis, D. A., & Gounaris, A. (2014) · PubMed · Cited by 95 · see citing works

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

Wilks, S. T. (2015) · The Breast · doi:10.1016/j.breast.2015.06.002 · Cited by 93 · see citing works

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer

Baker, A. T., Zlobin, A., & Osipo, C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00360 · Cited by 92 · see citing works

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer

Sharial, M. S. N. M., Crown, J. P., & Hennessy, B. T. (2012) · Annals of Oncology · doi:10.1093/annonc/mds200 · Cited by 90 · see citing works

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Garrett, J. T., Sutton, C. R., Kurupi, R., Bialucha, C. U., Ettenberg, S. A., Collins, S. D., Sheng, Q., Wallweber, J., Eli, L. D., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1191 · Cited by 87 · see citing works

The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions

Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Pirsalehi, A., Safaroghli‐Azar, A., Zali, M. R., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173983 · Cited by 87 · see citing works

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

Elster, N., Collins, D. M., Toomey, S., Crown, J. P., Eustace, A. J., & Hennessy, B. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3250-x · Cited by 87 · see citing works

Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy

Xu, J., Hu, S., Shen, G., & Shen, G. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0290-9 · Cited by 79 · see citing works

Resistance to Trastuzumab

Vivekanandhan, S., & Knutson, K. L. (2022) · Cancers · doi:10.3390/cancers14205115 · Cited by 76 · see citing works

PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Stern, H. M., Gardner, H., Burzykowski, T., Elatre, W. A., O'Brien, C. L., Lackner, M. R., Pestano, G. A., Santiago, A., Villalobos, I. E., EIERMANN, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2993 · Cited by 70 · see citing works

Beyond trastuzumab: New treatment options for HER2-positive breast cancer

Saini, K. S., Azim, H. A., Metzger, O., Loi, S., Sotiriou, C. P., de Azambuja, E., & Piccart, M. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70289-2 · Cited by 70 · see citing works

Roles of PTEN (Phosphatase and Tensin Homolog) in Gastric Cancer Development and Progression

Xu, W., Yang, Z., & Lü, N. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.17 · Cited by 69 · see citing works

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Veeraraghavan, J., Angelis, C. D., Reis-Filho, J. S., Pascual, T., Prat, A., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2017) · The Breast · doi:10.1016/j.breast.2017.06.022 · Cited by 67 · see citing works

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

De, P. K. R., Hasmann, M., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.006 · Cited by 66 · see citing works

New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available

Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 65 · see citing works

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer

Guarneri, V., Generali, D., Frassoldati, A., Artioli, F., Boni, C., Cavanna, L., Tagliafico, E., Maiorana, A., Bottini, A., Cagossi, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4737 · Cited by 61 · see citing works

Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy

Kim, H. S., Shin, S., Beom, S., Jung, M., Choi, Y. Y., Son, T., Kim, H., Cheong, J., Hyung, W. J., Noh, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10115 · Cited by 61 · see citing works

Downregulation of dihydrolipoyl dehydrogenase by UVA suppresses melanoma progression via triggering oxidative stress and altering energy metabolism

Yumnam, S., Kang, M. C., Oh, S. H., Kwon, H. C., Kim, J. C., Jung, E. S., Lee, C. H., Lee, A., Hwang, J., & Kim, S. Y. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.037 · Cited by 60 · see citing works

Gene of the month: PIK3CA

Lai, K., Killingsworth, M. C., & Lee, C. S. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202885 · Cited by 59 · see citing works

Loss of ARID1A Activates ANXA1 , which Serves as a Predictive Biomarker for Trastuzumab Resistance

Berns, K., Sonnenblick, A., Gennissen, A. M. C., Brohée, S., Hijmans, E. M., Evers, B., Fumagalli, D., Desmedt, C., Loibl, S., Denkert, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2996 · Cited by 59 · see citing works

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Lee, J. Y., Hong, M. E., Kim, S. T., Park, S. H., Kang, W. K., Kim, K.-M., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep09289 · Cited by 57 · see citing works

MicroRNA-induced drug resistance in gastric cancer

Dehghanzadeh, R., Jadidi‐Niaragh, F., Gharibi, T., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.009 · Cited by 56 · see citing works

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Zimmerman, B. S., & Esteva, F. J. (2024) · Cancers · doi:10.3390/cancers16040800 · Cited by 56 · see citing works

CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells

Boulbés, D. R., Chauhan, G. B., Jin, Q., Bartholomeusz, C., & Esteva, F. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3414-3 · Cited by 55 · see citing works

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

Milosevic, Z. C., Pešić, M., Stanković, T., Dinić, J., Milovanović, Z., Stojšić, J. M., Džodić, R. R., Tanić, N., & Banković, J. (2014) · Translational research · doi:10.1016/j.trsl.2014.06.005 · Cited by 55 · see citing works

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

Dokmanovic, M., Wu, Y., Shen, Y., Chen, J., Hirsch, D. S., & Wu, W. J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29171 · Cited by 55 · see citing works

Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer

Beg, S., Siraj, A. K., Prabhakaran, S., Jehan, Z., Ajarim, D. S., Al‐Dayel, F., Tulbah, A. M., & Al-Kuraya, K. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3430-3 · Cited by 55 · see citing works

New phosphatidylinositol 3-kinase inhibitors for cancer

Bowles, D. W., & Jimeno, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562192 · Cited by 54 · see citing works

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

Ramirez-Ardila, D. E., Helmijr, J., Look, M. P., Lurkin, I., Ruigrok-Ritstier, K., Laere, S. V., Dirix, L. Y., Sweep, F. C. G. J., Span, P. N., Linn, S. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2529-7 · Cited by 54 · see citing works

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer

Arienti, C., Zanoni, M., Pignatta, S., Río, A. D., Carloni, S., Tebaldi, M., Tedaldi, G., & Tesei, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7575 · Cited by 54 · see citing works

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

Wang, Y., Liu, Y., Du, Y., Yin, W., & Lu, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794775 · Cited by 53 · see citing works

Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)

Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53 · see citing works

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Wisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 52 · see citing works

Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0687 · Cited by 51 · see citing works

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 51 · see citing works

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

Gayle, S. S., Arnold, S. L. M., O'Regan, R. M., & Nahta, R. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799015002 · Cited by 50 · see citing works

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer

Farrugia, M. K., Sharma, S. B., Lin, C.-C., McLaughlin, S. L., Vanderbilt, D. B., Ammer, A. G., Salkeni, M. A., Stoilov, P., Agazie, Y. M., Creighton, C. J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.65 · Cited by 48 · see citing works

Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling

Tian, J., & Yuan, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.070 · Cited by 48 · see citing works

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

Park, Y. H., Jung, H. A., Choi, M. K., Chang, W., Choi, Y., Do, I.-G., Ahn, J. S., & Im, Y.-H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.757 · Cited by 47 · see citing works

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer

Kim, C., Lee, C., Chon, H. J., Kim, J. H., Park, H. S., Heo, S. J., Kim, H. J., Kim, T. S., Kwon, W. S., Chung, H. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23054 · Cited by 47 · see citing works

PIK 3 CA mutation profiling in patients with breast cancer, using a highly sensitive detection system

Shimoi, T., Hamada, A., Yamagishi, M., Hirai, M., Yoshida, M., Nishikawa, T., Sudo, K., Shimomura, A., Noguchi, E., Yunokawa, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13696 · Cited by 47 · see citing works

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

Wang, Q., Liu, P., Spangle, J. M., Von, T., Roberts, T. M., Lin, N., Krop, I. E., Winer, E. P., & Zhao, J. J. (2015) · Oncogene · doi:10.1038/onc.2015.406 · Cited by 46 · see citing works

Effect of HER2 status on distant recurrence in early stage breast cancer

Hess, K. R., & Esteva, F. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2366-0 · Cited by 45 · see citing works

Partial PTEN deletion is linked to poor prognosis in breast cancer

Lebok, P., Kopperschmidt, V., Kluth, M., Hube‐Magg, C., Özden, C., Taskin, B., Hussein, K. R., Mittenzwei, A., Lebeau, A., Witzel, I., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1770-3 · Cited by 45 · see citing works

The Role of PTEN in Tumor Angiogenesis

Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44 · see citing works

Meeting the needs of breast cancer: A nucleolin’s perspective

Gregório, A. C., Lacerda, M., Figueiredo, P., Simões, S., Dias, S., & Moreira, J. N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.008 · Cited by 44 · see citing works

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

Khokhar, N. Z., Altman, J. K., & Platanias, L. C. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834b892d · Cited by 43 · see citing works

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 43 · see citing works

Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy

Cadoo, K. A., Traina, T. A., & King, T. A. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.006 · Cited by 43 · see citing works

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

Brack, S., Attinger-Toller, I., Schade, B., Mourlane, F., Klupsch, K., Woods, R., Hachemi, H., von der Bey, U., Koenig-Friedrich, S., Bertschinger, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0046-t · Cited by 43 · see citing works

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

Boulbés, D. R., Arold, S. T., Chauhan, G. B., Blachno, K. V., Deng, N., Chang, W., Jin, Q., Huang, T.-H., Hsu, J.-M., Brady, S. W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.011 · Cited by 41 · see citing works

A pharmacogenomic method for individualized prediction of drug sensitivity

Cohen, A. L., Soldi, R., Zhang, H., Gustafson, A. M., Wilcox, R., Welm, B. E., Chang, J. T., Johnson, W. E., Spira, A. E., Jeffrey, S. S., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.47 · Cited by 42 · see citing works

Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells

Kharmate, G., Rajput, P. S., Lin, Y., & Kumar, U. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-93 · Cited by 42 · see citing works

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

Wang, Y., Liu, Y., Du, Y., Yin, W., & Lu, J. (2020) · Figshare · doi:10.6084/m9.figshare.11830110

PTEN loss is not associated with trastuzumab resistance in metastatic breast cancer.

Kocar, M., Bozkurtlar, E. B., Telli, F., Turhal, N. S., Kaya, H., Kocar, H., & Yumuk, F. (2014) · PubMed · Cited by 6 · see citing works

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627 · see citing works

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

Dave, B., Migliaccio, I., Gutierrez, M. C., Wu, M.-F., Chamness, G. C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S. G., Huang, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7814 · Cited by 252 · see citing works

Activation of the tumour suppressor PTEN as an alternative explanation for Trastuzumab's mechanism of action

Mano, M. S., Awada, A. H., Minisini, A. M., Durbecq, V., Leo, A. D., & Piccart, M. J. (2004) · The Breast · doi:10.1016/j.breast.2004.09.008